Abstract 1,3-Dioxan-5-yl pyrimidine and purine nucleoside analogues were prepared following a new and versatile synthetic strategy. These analogues were synthesized via nucleophilic addition of the selected nucleobase to a 1,3-dioxane scaffold that presents an appropriate leaving group in position 5. In particular cis and trans isomers of purine/pyrimidine nucleosides and their halogenated homologues were obtained. NMR experiments, carried out on the cis isomers, led to assignment of an equatorial orientation to the 2-hydroxymethyl group and axial orientation to the nucleobase in position 5 of the 1,3-dioxane. The trans isomers showed a diequatorial orientation of these groups. These assignments were confirmed by X-ray crystallographic studies.
The synthesis and biological evaluation of nucleoside analogues have been a very active research area for a number of years. 1, 2 Among them, a well-known class of molecules endowed with antiviral or anticancer activity was obtained by replacing the 2-deoxyribose moiety with a 1,3-dioxolane 3,4 or 1,3-oxathiolane ring. 5, 6 Based on the results reported, we focused part of our research on the synthesis of nucleoside analogues having these novel sugar-replacing rings. Furthermore, with the aim to investigate the properties of higher homologues of the 1,3-dioxolane-based nucleosides, 1,3-dioxane analogues were also considered (Figure 1) .
Although 1,3-dioxan-5-yl pyrimidines were previously reported as potential anti-HIV nucleoside alike compounds, 7, 8 we felt that the true value of a structural modification concerning the sugar portion would only be completely revealed when all nucleoside analogues were produced and evaluated. This consideration is supported by the case of 1,3-oxathiolane-based nucleosides in which only the cytosine analogue showed a good antiviral (i.e., HIV, HBV) potency and selectivity. 5 Supported by this evidence, we developed a novel synthetic approach to obtain the corresponding purine derivatives. Unlike the previously reported methods, the synthetic strategy presented herein allowed us to isolate and fully characterize both cis and trans isomers of all targeted derivatives. The 1,3-dioxane-based nucleosides were obtained by reacting each purine and pyrimidine base with a key intermediate in the last step of the synthetic pathway. This strategy avoids the expensive and time-consuming Mitsunobu-type condensation of bis-1,3-trityloxy-2-propanol with each nucleobase in the first step of the synthetic path. 7, 8 In addition, it overcomes the demanding separation of the cis/trans diastereoisomers to be performed on the precious and hard-to-handle nucleoside mixture. Moreover, the Mitsunobu reaction cannot be applied in the case of purines due to their poor solubility in the suitable reaction solvents. At present, 1,3-dioxan-5-ylpurine nucleosides have never been isolated and characterized. In this work we developed a different synthetic approach in order to obtain a large variety of cis-and transpyrimidine/purine nucleoside analogues by using a com- 
Letter Syn lett mon intermediate (Scheme 1). Diethyl acetal 1,
17 required as starting material, was prepared from sodium benzoate and bromoacetaldehyde diethyl acetal. Synthesis of the 1,3-dioxane ring was accomplished by Lewis acid mediated condensation of 1 with glycerol to give compound 2.
9,18 The reaction proceeds without stereoselectivity and regioselectivity preferences, giving cis (2a) 19 and trans (2b) 20 isomers in comparable yields as well as their corresponding 1,3-dioxolane isomers. The molar ratio of 1,3-dioxane/1,3-dioxolane cis,trans-diastereoisomeric mixture was 55:45. However, due to the marked difference in polarity, the single diastereoisomers of 2 were easily separated by flash column chromatography and obtained in high purity free from their lower homologues (1,3-dioxolanes) . Treatment of 2a and 2b with p-toluenesulfonyl chloride gave the key intermediates 3a and 3b, 21 respectively. Nucleophilic displacement of the tosyl group by the selected nucleobase produced an inversion of the configuration at C-5 of the 1,3-dioxane and furnished trans (4a-13a) and cis isomers (4b-13b), 22-24 respectively, of the desired nucleosides. Deprotection of the hydroxyl group in position 2 of the 1,3-dioxane with NH 3 -H 2 O and the subsequent crystallization gave the final pyrimidine nucleosides as pure trans (14a-21a) or cis diastereoisomers (14b-21b; Scheme 1, Table 1 ).
25
The desired adenine analogues 22a and 22b 26 were obtained by treatment of the parent compounds 12a and 12b with saturated NH 3 -H 2 O, in a reactor at 100 °C. Compounds 13a and 13b were transformed into the final guanine nucleosides 23a and 23b
27 by heating at 100 °C in the presence of aqueous NaOH-methanol solution (Scheme 1).
Stereochemical and conformational assignments were based on NMR studies. The relative chemical shifts of the H-5′ (1,3-dioxane) and H-6 (pyrimidine) or H-8 (purine) were 
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taken into account to assign the cis/trans configurations to all final compounds 14-23 ( Figure 2 and Table 2 ). In particular, the H-5′ signal of the trans isomers appears downfield with respect to that of the corresponding cis isomers. This result is probably due to the deshielding effect of the 1,3-dioxane oxygen atoms, suggesting an axial orientation of H-5′. Alternatively, in the cis isomers the H-5′ proton is arranged equatorially so that the nucleobase presents an axial orientation. The deshielding effect of the oxygen atoms is exerted also on H-6 of the pyrimidine or on H-8 of the purine. In particular, when the base is axially oriented, as in the cis isomers, the signal of these protons falls at lower field with respect to that of the corresponding trans isomer. Moreover, the pattern of all H-5′ protons unambiguously confirmed that in all cis isomers the nucleobase is axially oriented while in trans isomers the base has equatorial orientation ( Figure 2 ). In fact, for the cis isomers, the H-5′ peak is a broadened singlet with two small coupling constants. This evidence is in good agreement with an equatorial orientation of this proton when 2′,5′-disubstituted 1,3-dioxanes show a C-2′,C-5′ cis configuration. By contrast, the H-5′ signal of the trans isomers appears as a defined multiplet, with two large coupling constants that indicate its axial ori- H NMR studies on 2′,5′-disubstituted 1,3-dioxane analogues. 7, 8, 10 The NMR structural elucidations were further supported by X-ray crystallographic studies. The crystals of 22b, obtained from aqueous solution, were analyzed by single-crystal X-ray diffraction at room temperature. The crystals were monoclinic (space group P2 1 /c) with four molecules per unit cell. Bond lengths and angles are unexceptional, as compared with those found in cyclohexyl 11 and pyranosyl 12 derivatives of adenine. The 1,3-dioxane ring adopts a chair conformation, with the adenine and hydroxymethyl groups in axial and equatorial positions, respectively (Figure 3 ).
Figure 3
Partially labeled ORTEP-3 plot of 22b, with displacement ellipsoids at 40% probability level and H atoms drawn as spheres with arbitrary radius.
14 Only H atoms bound to heteroatoms are labeled.
The purine base is in the anti orientation with respect to the 1,3-dioxane ring, as shown by the torsion angle C7-C6-N1-C5, -151.31(7)°. The molecular structure is remarkably similar to that of trans-9-(2-ethoxy-1,3-dioxan-5-yl)adenine, which, however, features the ethoxy substituent in axial position. 13 In the crystal lattice, complementary donor-acceptor interactions link molecules in chains that run parallel to the c axis. The hydroxyl oxygen atom O3 is hydrogen-bonded to the imidazole nitrogen atom N2 of a neighboring molecule [O3-HO3···N2 2.7759(11) Å]. In turn, the exocyclic amino group of the latter acts as a hydrogen donor towards one of the 1,3-dioxane ring oxygens [N5-HN5a···O2 3.0265(11) Å]. These chains are connected to each other via a third hydrogen bond that involves the remaining amino hydrogen and the pyrimidine nitrogen atom N3 [N5-HN5b···N3 3.0645(10) Å]. The crystal structure is further stabilized by short C-H···O contacts and base-stacking interactions.
All synthesized nucleosides 14-23 were evaluated for their potential activity against a variety of viruses following the previously described procedures. 15 None of the compounds showed significant antiviral activity against human immunodeficiency virus type 1 and 2 (HIV-1, HIV-2), herpes simplex virus type 1 and 2 (HSV-1, HSV-2), vaccinia virus and vescicular stomatitis virus (VSV) in infected MT-4 (for HIV) or HEL (other viruses) cell cultures. Moreover no microscopically visible cytotoxicity was observed at the highest concentrations tested (i.e., 200 μM) of all compounds. The compounds were also evaluated for cytotoxic effects towards several human cancer cell lines such as HCT116 (colon), A549 (lung), SNU638 (stomach), PC3 (prostate), SK-Hep-1 (liver), using sulforhodamine B (SRB) protein staining method. 16 None of the tested compounds showed significant antitumor activity, with an EC 50 value > 100 μM.
In summary, a new and versatile synthesis of achiral 1,3-dioxan-5-yl-based nucleosides (pyrimidin-1-yl/purin-9-yl) has been developed. This synthetic strategy allows both cis and trans diastereoisomers of all purine and pyrimidine analogues to be obtained. Furthermore, 1,3-dioxan-5-yl purines were isolated and structurally characterized for the first time. None of the compounds possesses significant antiviral and antitumor activity in the biological assays performed. Further or different modifications have to be introduced to unlock the antiviral/antitumor activity. However, this synthetic approach may represent a valuable tool for obtaining new analogues of this class of compounds.
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